p53-dependent global nucleotide excision repair of cisplatin-induced intrastrand cross links in human cells

Mutagenesis

Volumn 23, Issue 2, 2008, Pages 131-136

  Bhana, Sara ^a   Hewer, Alan ^b   Phillips, David H ^b   Lloyd, Daniel R ^a  

^a UNIVERSITY OF KENT   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL EXTRACT; CISPLATIN; PHOSPHORUS 32; PROTEIN P53; TETRACYCLINE; ANTINEOPLASTIC AGENT; CROSS LINKING REAGENT; DINUCLEOSIDE PHOSPHATE; DNA; GUANYLYL (3' 5') GUANOSINE; GUANYLYL-(3'-5')-GUANOSINE; PHOSPHORUS; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DNA CROSS LINKING; DNA DAMAGE; DNA STRAND; EXCISION REPAIR; FIBROBLAST; GENOME; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; WHOLE CELL; CHEMISTRY; DNA REPAIR; DRUG EFFECT; GENETICS; ISOTOPE LABELING; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL EXTRACTS; CELL LINE, TUMOR; CISPLATIN; CROSS-LINKING REAGENTS; DINUCLEOSIDE PHOSPHATES; DNA; DNA ADDUCTS; DNA REPAIR; HUMANS; ISOTOPE LABELING; PHOSPHORUS RADIOISOTOPES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 41449103567     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/gen001     Document Type: Article

References (33)

1. Shelley, M. D., Burgon, K. and Mason, M. D. (2002) Treatment of testicular germ-cell cancer: a Cochrane evidence-based systematic review. Cancer Treat. Rev., 28, 237-253.
2. Baik, M.-H., Friesner, R. A. and Lippard, S. J. (2003) Theoretical study of cisplatin binding to purine bases: why does cisplatin prefer guanine over adenine? J. Am. Chem. Soc., 125, 14082-14092.
3. Fichtinger-Schepman, A. J., van der Veer, J. L., den Hartog, J. H. J., Lohman, P. H. M. and Reedijk, J. (1985) Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation. Biochemistry, 24, 707-713.
4. Kartalou, M. and Essigmann, J. M. (2001) Recognition of cisplatin adducts by cellular proteins. Mutat. Res., 478, 1-21.
5. Tornaletti, S., Patrick, S. M., Turchi, J. J. and Hanawalt, P. C. (2003) Behavior of T7 RNA polymerase and mammalian RNA polymerase II at site-specific cisplatin adducts in the template DNA. J. Biol. Chem., 278, 35791-35797.
6. Mello, J. A., Acharya, S., Fishel, R. and Essigmann, J. M. (1996) The mismatch repair protein hMSH2 binds selectively to DNA adducts of the anti-cancer drug cisplatin. Chem. Biol., 3, 579-589.
7. Zamble, D. B., Mu, D., Reardon, J. T., Sancar, A. and Lippard, S. J. (1996) Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry, 35, 10004-10013.
8. Wang, D., Hara, R., Singh, G., Sancar, A. and Lippard, S. J. (2003) Nucleotide excision repair from site-specifically platinum-modified nucleosomes. Biochemistry, 42, 6747-6753.
9. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. and Craig, R. W. (1991) Participation of p53 in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
10. Lowe, S. W. and Lin, A. W. (2001) Apoptosis in cancer. Carcinogenesis, 21, 485-495.
11. Ford, J. M. and Hanawalt, P. C. (1995) Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV-resistance. Proc. Natl Acad. Sci. USA., 92, 8876-8880.
12. Ford, J. M. and Hanawalt, P. C. (1997) Expression of wild type p53 is required for efficient global nucleotide excision repair in UV-irradiated human fibroblasts. J. Biol. Chem., 272, 28073-28080.
13. Ford, J. M., Baron, E. L. and Hanawalt, P. C. (1998) Human fibroblasts expressing the human papilloma virus E6 gene are deficient in global genomic nucleotide excision repair and sensitive to ultraviolet irradiation. Cancer Res., 58, 599-603.
14. Bowman, K. K., Sicard, D. M., Ford, J. M. and Hanawalt, P. C. (2000) Reduced global genomic repair of ultraviolet light-induced cyclobutane pyrimidine dimers in simian virus 40-transformed cells. Mol. Carcinog., 29, 17-24.
15. Lloyd, D. R. and Hanawalt, P. C. (2000) p53-dependent global genomic repair of benzo(a)pyrene-7,8-diol-9,10-epoxide adducts in human cells. Cancer Res., 60, 517-521.
16. Wani, M. A., Zhu, Q., El-Mahdy, M., Venkatachalam, S. and Wani, A. A. (2000) Enhanced sensitivity to anti-benzo(a)pyrene-diol-epoxide DNA damage correlates with decreased global genomic repair attributable to abrogated p53 function in human cells. Cancer Res., 60, 2273-2280.
17. Lloyd, D. R. and Hanawalt, P. C. (2002) p53 controls global nucleotide excision repair of structurally diverse benzo(g)chrysene adducts in human fibroblasts. Cancer Res., 62, 5288-5294.
18. Fan, J. and Bertino, J. R. (1999) Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. Mol. Pharmacol., 56, 966-972.
19. 1 cell cycle checkpoints and mediated reversible growth arrest in human fibroblasts. Proc. Natl Acad. Sci. USA., 92, 8493-8497.
20. Gupta, R. C. (1984) Non-random binding of the carcinogen N-hydroxy-2-acetylaminofluorene to repetitive sequences of rat liver DNA in vivo. Proc. Natl Acad. Sci. USA., 81, 6943-6947.
21. 32P-postlabeling assay for the quantitation of the major platinum-DNA adducts. Carcinogenesis, 18, 1767-1774.
22. 32P-postlabeling. Nucleic Acids Res., 23, 1300-1306.
23. Bargonetti, J., Reynisdottir, I., Friedman, P. N. and Prives, C. (1992) Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. Genes Dev., 6, 1886-1898.
24. Sheppard, H. M., Corneillie, S. I., Espiritu, C., Gatti, A. and Liu, X. (1999) New insights into the mechanism of inhibition of p53 by simian virus 40 large T antigen. Mol. Cell. Biol., 19, 2746-2753.
25. Xing, J., Sheppard, H. M., Corneillie, S. I. and Liu, X. (2001) p53 stimulated TFIID-TFIIA-promoter complex assembly, and p53-T antigen complex inhibits TATA binding protein-TATA interaction. Mol. Cell. Biol., 21, 3652-3661.
26. Bhana, S. and Lloyd, D. R. (2008) The role of p53 in DNA damage-mediated cytotoxicity overrides its ability to regulate nucleotide excision repair in human fibroblasts. Mutagenesis, 23, 43-50.
27. Pestell, K. E., Hobbs, S. M., Titley, J. C., Kelland, L. R. and Walton, M. R. (2000) Effect of p53 status on sensitivity to platinum complexes in a human ovarian cell line. Mol. Pharmacol., 57, 503-511.
28. Park, C. M., Park, M. J., Kwak, H. J., Moon, S. I., Yoo, D. H., Lee, H. C., Park, I. C., Rhee, C. H. and Hong, S. I. (2006) Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int. J. Oncol., 28, 119-125.
29. Mandic, R., Schamberger, C. J., Muller, J. F., Geyer, M., Zhu, L., Carey, T. E., Grenman, R., Dunne, A. A. and Werner, J. A. (2005) Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localisation signal of p53. Clin. Cancer Res., 11, 6845-6852.
30. Vekris, A., Meynard, D., Haaz, M.-C., Bayssas, M., Bonnet, J. and Robert, J. (2004) Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res., 64, 356-362.
31. Spierings, D. C., de Vries, E. G., Vellenga, E. and de Jong, S. (2003) The attractive Achilles heel of germ cell tumours: and inherent sensitivity to apoptosis-inducing stimuli. J. Pathol., 200, 137-148.
32. Schuijer, M. and Berns, E. M. J. J. (2003) TP53 and ovarian cancer. Hum. Mutat., 21, 285-291.
33. Meek, D. (2004) The p53 response to DNA damage. DNA Repair, 3, 1049-1056.